Literature DB >> 25232245

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Kareem Hassan1, Varun Bhalla1, Mohammed Ezz El Regal1, H Hesham A-Kader1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is quickly becoming one of the most prominent causes of liver disease worldwide. The increasing incidence of NAFLD is tied to the obesity epidemic and the subsequent metabolic derangements brought along with it. Current efforts to elucidate the mechanism and causes of the disease have answered some questions, but much remains unknown about NAFLD. The aim of this article is to discuss the current knowledge regarding the pathogenesis of the disease, as well as the current and future diagnostic, preventative, and therapeutic options available to clinicians for the management of NAFLD.

Entities:  

Keywords:  Diagnosis; Imaging; Management; Metformin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pathogenesis; Prevalence; Steatohepatitis; Thiazolidinedione; Treatments; Vitamin E

Mesh：

Year:  2014        PMID： 25232245      PMCID： PMC4161796          DOI： 10.3748/wjg.v20.i34.12082

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  231 in total

Review 1.  Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.

Authors:  Leon A Adams; Ariel E Feldstein
Journal:  J Dig Dis       Date:  2011-02       Impact factor: 2.325

2.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

3.  Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Authors:  Yunes Panahi; Mohammad Ebrahim Ghamarchehreh; Fatemeh Beiraghdar; Rnmarjan Zare; Hamid Reza Jalalian; Amirhossein Sahebkar
Journal:  Hepatogastroenterology       Date:  2012-10

4.  Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Authors:  Temitope Foster; Matthew J Budoff; Sammy Saab; Naser Ahmadi; Craig Gordon; Alan D Guerci
Journal:  Am J Gastroenterol       Date:  2010-09-14       Impact factor: 10.864

5.  Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome.

Authors:  Achim Lass; Robert Zimmermann; Guenter Haemmerle; Monika Riederer; Gabriele Schoiswohl; Martina Schweiger; Petra Kienesberger; Juliane G Strauss; Gregor Gorkiewicz; Rudolf Zechner
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

6.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.

Authors:  L Chao; B Marcus-Samuels; M M Mason; J Moitra; C Vinson; E Arioglu; O Gavrilova; M L Reitman
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.

Authors:  Robert K Semple; Alison Sleigh; Peter R Murgatroyd; Claire A Adams; Les Bluck; Sarah Jackson; Alessandra Vottero; Dipak Kanabar; Valentine Charlton-Menys; Paul Durrington; Maria A Soos; T Adrian Carpenter; David J Lomas; Elaine K Cochran; Phillip Gorden; Stephen O'Rahilly; David B Savage
Journal:  J Clin Invest       Date:  2009-01-26       Impact factor: 14.808

Review 9.  Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Authors:  Layli Eslami; Shahin Merat; Reza Malekzadeh; Siavosh Nasseri-Moghaddam; Hermineh Aramin
Journal:  Cochrane Database Syst Rev       Date:  2013-12-27

10.  Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Authors:  Bertrand Cariou; Rémy Hanf; Stéphanie Lambert-Porcheron; Yassine Zaïr; Valérie Sauvinet; Benoit Noël; Laurent Flet; Hubert Vidal; Bart Staels; Martine Laville
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112
View more
  59 in total

Review 1.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

2.  Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.

Authors:  Tian Shen; Bilin Xu; Tao Lei; Lin Chen; Cuiping Zhang; Zhenhua Ni
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

Review 3.  Carotenoids and non-alcoholic fatty liver disease.

Authors:  Bahiddin Yilmaz; Kazim Sahin; Hande Bilen; Ibrahim H Bahcecioglu; Birdal Bilir; Sara Ashraf; Karim J Halazun; Omer Kucuk
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

4.  A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.

Authors:  Steven E Trasino; Xiao-Han Tang; Jose Jessurun; Lorraine J Gudas
Journal:  J Mol Med (Berl)       Date:  2016-06-06       Impact factor: 4.599

5.  Pediatric Fatty Liver Disease.

Authors:  Ajay Jain
Journal:  Mo Med       Date:  2019 Mar-Apr

6.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

7.  Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.

Authors:  Lu Gan; Zi-jun Meng; Ri-bo Xiong; Jin-qiang Guo; Xiao-cui Lu; Zhi-wei Zheng; Yan-ping Deng; Bing-de Luo; Fei Zou; Hua Li
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

Review 8.  Biliverdin reductase and bilirubin in hepatic disease.

Authors:  Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-01       Impact factor: 4.052

Review 9.  Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review.

Authors:  Harleen K Dyal; Maria Aguilar; Taft Bhuket; Benny Liu; Edward W Holt; Sharon Torres; Ramsey Cheung; Robert J Wong
Journal:  Dig Dis Sci       Date:  2015-07-03       Impact factor: 3.199

Review 10.  Promising therapies for treatment of nonalcoholic steatohepatitis.

Authors:  Mazen Noureddin; Alice Zhang; Rohit Loomba
Journal:  Expert Opin Emerg Drugs       Date:  2016-08-28       Impact factor: 4.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.